Policy Developments - Abbott Molecular Inc. has initiated a recall of its automated real-time fluorescent nucleic acid amplification analysis system due to design defects [1] - Other companies including Ortho Clinical Diagnostics, Leica Biosystems, Beckman Coulter, and Aesculap have also recalled products due to various issues such as potential bias in reportable range, incorrect labeling, cross-contamination, and rising complaint trends [1] Drug and Device Approvals - Jianyou Co., Ltd. has received FDA approval for the production site transfer of its Idarubicin Hydrochloride Injection in multiple dosages [2] - Xinhua Pharmaceutical has been granted approval for the listing of Eicosapentaenoic Acid Ethyl Ester as a chemical raw material drug [3] Capital Market Activities - Guangzhou Pharmaceutical, a subsidiary of Baiyunshan, will be listed on the New Third Board starting May 20, 2025 [4] - Chuangxin International has completed nearly 100 million RMB in Series B financing led by Yueke Fund and Zhongshan Haochuang Fund [5] Industry Events - Kanghui Pharmaceutical has won a first-instance judgment in a lawsuit against Kelewei Biopharmaceuticals regarding equity repurchase, requiring Kelewei to pay 2 million RMB in deposit and 35.994 million RMB in repurchase funds [6] - Weigao Blood Purification Products Co., Ltd. has officially listed on the Shanghai Stock Exchange, raising approximately 1.09 billion RMB through its IPO [7] Public Sentiment Alerts - Sanleaf Bio has changed its accounting firm due to disagreements over audit fees [8] Management Changes - Dize Pharmaceutical's executives plan to reduce their shareholdings due to personal financial needs, with specific amounts detailed for each individual [9][10] - Jia Ying Pharmaceutical's CFO has resigned for personal reasons and will no longer hold any position within the company [11]